Oppenheimer raised its target from $18 to $21 and kept its Outperform rating after Xeris's recent third-quarter report. The favorable analyst view supports a positive read, though it is an opinion rather than a new company result.
The higher target gives a more favorable outside view of Xeris's growth prospects. But it is an analyst's judgment, not a new company result. The firm kept its positive rating after the recent third-quarter report.
Follow Xeris Biopharma Holdings, Inc. (XERS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for XERS